ASHLAND INC. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Ashland reported Q4 FY2026 (ended Sept 30, 2026) sales of $498M (+4% YoY), adjusted EBITDA of $121M (+2% YoY), and adjusted EPS of $1.12 (up from $1.08). Full-year FY2026 sales were $1.863B (+2% YoY); adjusted EBITDA $385M (down 4% from $401M); adjusted EPS $3.31 (down from $3.38). FY2027 guidance: sales $1.905-1.975B (2-6% growth); adjusted EBITDA $405-435M; FCF conversion >40%. Life Sciences and Personal Care drove growth; Specialty Additives productivity lagged.
Why this rating
Modest organic growth and stable guidance; Hopewell productivity headwinds and FY27 EBITDA guidance midpoint ($420M) essentially flat vs FY26 ($385M adjusted). Relative to $2.7B market cap, incremental gains are meaningful but not transformational.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.